Tag: Depression
Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults ... Read More
Lupin receives FDA nod for Chlorpromazine Hydrochloride Tablets
Lupin Inc., a wholly-owned subsidiary of the global pharmaceutical major Lupin Limited, announced that it has received approval from the United States Food and Drug ... Read More
Zydus Lifesciences gets FDA final approval for Olanzapine tablets
Zydus Lifesciences said that it has secured final approval for Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10mg, 15 mg, and 20 mg from the ... Read More
Dr. Reddy’s Laboratories launches Venlafaxine ER Tablets in US
Dr. Reddy’s Laboratories said that it has launched Venlafaxine ER Tablets, which is therapeutically equivalent to Osmotica Pharmaceutical US’ Venlafaxine Extended-Release Tablets, 150 mg and ... Read More
Zydus Cadila gets FDA’s final approval for Vortioxetine Tablets
Zydus Cadila has secured final approval from the US Food and Drug Administration (FDA) to market Vortioxetine Tablets in the strengths of 5mg, 10mg, 20mg ... Read More
Unichem Laboratories gets FDA approval for Amitriptyline HCl Tablets generic
Unichem Laboratories, an Indian specialty pharma company, said that it has secured abbreviated new drug application (ANDA) approval for its Amitriptyline HCl Tablets USP, 10 ... Read More
Alembic Pharmaceuticals gets FDA approval for Lurasidone Hydrochloride Tablets
Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lurasidone Hydrochloride Tablets, ... Read More
Usona Institute gets FDA breakthrough status for psilocybin in MDD
Wisconsin-based Usona Institute has been granted breakthrough therapy designation for psilocybin from the US Food and Drug Administration (FDA) for the treatment of major depressive ... Read More
ZULRESSO postpartum depression drug set to be launched in US by Sage Therapeutics
CNS biopharma company Sage Therapeutics is all set to commercially launch its ZULRESSO (brexanolone) injection in the US later this month for the treatment of ... Read More
Janssen depression medication esketamine nasal spray yields mixed results in phase 3 trial
Janssen Pharmaceutical Companies of Johnson & Johnson depression medication esketamine nasal spray did not meet expectations in a phase 3 trial in patients with treatment-resistant ... Read More